ChromaDex (NASDAQ:CDXC) Trading Down 8.1% – Time to Sell?

Shares of ChromaDex Co. (NASDAQ:CDXC) traded down 8.1% during mid-day trading on Thursday . The stock traded as low as $7.97 and last traded at $7.86. 1,034,433 shares changed hands during trading, an increase of 25% from the average session volume of 826,390 shares. The stock had previously closed at $8.55.

Analyst Upgrades and Downgrades

Several equities analysts have recently commented on CDXC shares. Roth Mkm increased their price objective on ChromaDex from $6.00 to $8.00 and gave the company a “buy” rating in a research report on Wednesday, November 6th. LADENBURG THALM/SH SH lifted their price target on shares of ChromaDex from $6.80 to $8.10 and gave the stock a “buy” rating in a research note on Wednesday. Finally, StockNews.com raised shares of ChromaDex from a “buy” rating to a “strong-buy” rating in a report on Monday, February 24th.

ChromaDex Stock Performance

The company’s 50-day simple moving average is $5.68 and its two-hundred day simple moving average is $5.13. The firm has a market cap of $587.39 million, a PE ratio of 767.87 and a beta of 2.21.

Insider Activity at ChromaDex

In other ChromaDex news, Director Frank L. Jaksch, Jr. sold 37,161 shares of the company’s stock in a transaction that occurred on Friday, December 13th. The shares were sold at an average price of $6.19, for a total value of $230,026.59. Following the completion of the transaction, the director now directly owns 244,179 shares in the company, valued at $1,511,468.01. This represents a 13.21 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. 9.64% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

Several hedge funds have recently bought and sold shares of CDXC. Barclays PLC grew its holdings in ChromaDex by 322.1% during the 3rd quarter. Barclays PLC now owns 70,072 shares of the company’s stock valued at $256,000 after buying an additional 53,472 shares in the last quarter. Sargent Investment Group LLC purchased a new position in shares of ChromaDex in the 4th quarter worth approximately $263,000. FMR LLC acquired a new stake in ChromaDex during the 3rd quarter worth about $55,000. JPMorgan Chase & Co. increased its stake in shares of ChromaDex by 11.1% in the third quarter. JPMorgan Chase & Co. now owns 331,916 shares of the company’s stock worth $1,211,000 after acquiring an additional 33,150 shares during the period. Finally, State Street Corp boosted its holdings in ChromaDex by 11.3% in the third quarter. State Street Corp now owns 618,028 shares of the company’s stock valued at $2,256,000 after purchasing an additional 62,692 shares during the last quarter. Institutional investors own 15.41% of the company’s stock.

About ChromaDex

ChromaDex Corporation operates as a bioscience company focusing on developing healthy aging products. The company operates through three segments: Consumer products; Ingredients; and Analytical Reference Standards and Services. It researches nicotinamide adenine dinucleotide (NAD+); provides finished dietary supplement products that contain its proprietary ingredients directly to consumers and distributors; and develops and commercializes proprietary-based ingredient technologies and supplies these ingredients as raw materials to the manufacturers of consumer products.